Respiratory conditions - quality prescribing strategy: improvement guide 2024 to 2027

Respiratory conditions are a major contributor to ill health, disability, and premature death – the most common conditions being asthma and COPD. This quality prescribing guide is designed to ensure people with respiratory conditions are at the centre of their treatment.

9. Respiratory Prescribing Data for NHS Health Board

This chapter contains some top-level prescribing information comparing NHS Boards. Chart 12 below highlights the cost per treated patient which has decreased by £17.00 in NHS Scotland between 2020/21 and 2022/23.

Chart 12: Respiratory Costs per treated patient
Chart showing variance in respiratory costs per treated patient across all health boards and Scotland from 2020 to 2023. Overall Scotland trend is decreasing

Generic Prescribing

National and local guidance promotes branded prescribing of all inhalers excluding salbutamol inhalers. This ensures that the correct inhaler device and product is given to the individual (e.g. formulations of inhaled corticosteroids differ in potency). Chart 13 shows prescribing of generic inhalers across health boards, showing improvements across all boards.

Chart 13: Proportion of generically prescribed inhalers as a proportion of all inhalers (excluding salbutamol)
Chart showing variance of generically prescribed inhalers across all health boards and Scotland from 2021 to 2023. Overall Scotland trend is decreasing



Back to top